Your browser is no longer supported. Please, upgrade your browser.
Settings
RXII RXi Pharmaceuticals Corporation daily Stock Chart
RXII [NASD]
RXi Pharmaceuticals Corporation
Index- P/E- EPS (ttm)-3.26 Insider Own4.30% Shs Outstand4.26M Perf Week-20.36%
Market Cap1.93M Forward P/E- EPS next Y-1.23 Insider Trans0.00% Shs Float3.74M Perf Month-64.88%
Income-8.60M PEG- EPS next Q-0.38 Inst Own26.50% Short Float19.32% Perf Quarter-75.90%
Sales0.10M P/S20.10 EPS this Y66.40% Inst Trans- Short Ratio0.83 Perf Half Y-83.53%
Book/sh0.80 P/B0.57 EPS next Y34.60% ROA-179.10% Target Price3.00 Perf Year-91.08%
Cash/sh- P/C- EPS next 5Y- ROE-378.70% 52W Range0.40 - 7.70 Perf YTD-91.85%
Dividend- P/FCF- EPS past 5Y60.30% ROI- 52W High-94.22% Beta1.99
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low11.25% ATR0.13
Employees15 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)27.16 Volatility15.79% 14.53%
OptionableNo Debt/Eq0.00 EPS Q/Q58.70% Profit Margin- Rel Volume7.40 Prev Close0.45
ShortableYes LT Debt/Eq0.00 EarningsNov 13 AMC Payout- Avg Volume870.67K Price0.44
Recom2.00 SMA20-48.40% SMA50-64.53% SMA200-82.43% Volume4,593,592 Change-1.77%
Jun-07-16Resumed H.C. Wainwright Buy $3.50
Mar-31-15Reiterated H.C. Wainwright Buy $9 → $5
Jun-02-14Initiated Laidlaw Buy $8
May-05-14Initiated H.C. Wainwright Buy $9
Oct-08-18 10:50AM  RXII: Dilution Impact from Share Issuance Zacks Small Cap Research -9.00%
Oct-03-18 04:31PM  RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering PR Newswire
Oct-01-18 06:10AM  RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering PR Newswire -49.57%
Sep-28-18 08:26AM  Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals and Geron ACCESSWIRE -28.22%
Sep-26-18 08:00AM  RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference PR Newswire +6.72%
Sep-04-18 10:30AM  RXII: Dermal & Ocular Assets Available for Sale Zacks Small Cap Research
Aug-15-18 04:37PM  Edited Transcript of RXII earnings conference call or presentation 14-Aug-18 8:30pm GMT Thomson Reuters StreetEvents -6.96%
09:25AM  RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors PR Newswire
Aug-14-18 02:30PM  RXi Pharmaceuticals Corporation to Host Earnings Call ACCESSWIRE -5.95%
09:15AM  RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights PR Newswire
Aug-13-18 10:20PM  Alnylam drug approval marks watershed moment for gene-silencing field American City Business Journals
Aug-07-18 07:15AM  RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 PR Newswire
Aug-02-18 02:00PM  RXII: RXI-109 Results! Finally... Zacks Small Cap Research
09:25AM  RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan PR Newswire
08:00AM  Todays Research Reports on Stocks to Watch: RXi Pharmaceuticals and Neurocrine Biosciences ACCESSWIRE
Aug-01-18 09:25AM  RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring PR Newswire +20.95%
Jul-06-18 07:45AM  Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks ACCESSWIRE +5.92%
Jun-28-18 08:00AM  BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury PR Newswire
08:00AM  BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury Business Wire
Jun-06-18 07:25AM  Sangamo Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
May-18-18 11:58AM  RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts PR Newswire +8.94%
May-15-18 07:10AM  Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration ACCESSWIRE -5.60%
May-11-18 03:16PM  Edited Transcript of RXII earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents +6.25%
11:45AM  RXII: Partner Relationships in TILs to Drive Future Value Zacks Small Cap Research
08:58AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:23AM  RXi Pharma shares surge 10% premarket after news of partnership with Iovance MarketWatch
07:05AM  RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors PR Newswire
May-10-18 07:05AM  RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights PR Newswire +10.34%
May-08-18 02:20PM  RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO PR Newswire -5.33%
May-01-18 07:05AM  RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference PR Newswire
Apr-25-18 07:40AM  Blog Exposure - Codexis Entered into Strategic Collaboration with Porton Pharma Solutions ACCESSWIRE
Apr-24-18 07:05AM  RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018 PR Newswire
12:11AM  Norway's PCI Biotech sees promising data ahead of key study -CEO Reuters
Apr-16-18 11:25AM  RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma PR Newswire
Apr-11-18 12:56PM  RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering PR Newswire
Apr-09-18 02:04PM  RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market PR Newswire -5.08%
Apr-05-18 08:20AM  Todays Research Reports on Trending Tickers: Vericel Corporation and RXi Pharmaceuticals ACCESSWIRE
Apr-04-18 09:45AM  RXII: TIL Program Moving Forward while Waiting on Partnerships Zacks Small Cap Research +24.91%
07:05AM  RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference PR Newswire
Mar-27-18 03:52PM  Edited Transcript of RXII earnings conference call or presentation 26-Mar-18 9:00pm GMT Thomson Reuters StreetEvents -18.97%
Mar-26-18 04:40PM  RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights PR Newswire
12:00PM  RXi Pharmaceuticals Corporation to Host Earnings Call ACCESSWIRE
Mar-22-18 08:30AM  RXi Pharmaceuticals Discusses the Immuno-Oncology Space and Target Indications in New SNNLive Video Interview with StockNewsNow.com ACCESSWIRE -5.14%
Mar-21-18 01:00PM  RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018 PR Newswire -7.36%
Mar-20-18 07:05AM  RXi Pharmaceuticals Selected to Present at the Landmark Venture Forum PR Newswire
Mar-15-18 10:59AM  Focused on Speculative Trading: RXII, BB, CASA TheStreet.com +12.09%
08:20AM  Todays Research Reports on Trending Tickers: Novavax and RXi Pharmaceuticals ACCESSWIRE
Mar-08-18 04:59PM  RXi Pharmaceuticals Corporation (NASDAQ:RXII): Does The -60.33% Earnings Decline Make It An Underperformer? Simply Wall St. +10.78%
Mar-02-18 10:15AM  RXII: Exploiting a Natural Mechanism: RXis sd-rxRNA Zacks Small Cap Research
Feb-05-18 07:05AM  RXi Pharmaceuticals to Present at the BIO CEO and Investor Conference PR Newswire -8.63%
Jan-24-18 12:06PM  RXi Pharmaceuticals Regains Compliance with NASDAQ Listing Requirements PR Newswire
Jan-17-18 07:05AM  RXi Pharmaceuticals to Present at Immuno-Oncology Frontiers World Conference PR Newswire
Jan-16-18 07:05AM  RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth PR Newswire
Jan-09-18 07:20AM  Blog Exposure - RXi Pharma to Execute Reverse Stock Split ACCESSWIRE
Jan-05-18 12:45PM  RXi Pharmaceuticals Announces Reverse Stock Split PR Newswire -8.79%
Dec-29-17 07:05AM  RXi Pharmaceuticals to Present at the 10th Annual Biotech Showcase Conference PR Newswire
Dec-21-17 08:00AM  Streetwise Reports Examines How 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform GlobeNewswire
Dec-18-17 07:05AM  RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring PR Newswire
Dec-13-17 07:30AM  Wired News Medigene Announced Collaboration with RXi Pharma to Further Improve its Therapeutic T Cells ACCESSWIRE
Dec-11-17 07:05AM  Medigene Collaborates with RXi Pharmaceuticals to Further Sharpen its Therapeutic T cells PR Newswire
Dec-07-17 11:00AM  RXII: sd-rxRNA: A Flexible Platform for Oncology Zacks Small Cap Research
Dec-01-17 07:05AM  RXi Pharmaceuticals and the Center for Cancer Immune Therapy at Herlev Hospital Announce Research Collaboration PR Newswire
Nov-29-17 07:05AM  RXi Pharmaceuticals Announces Positive Results with RXI-231 in Consumer Testing Program PR Newswire
Nov-21-17 11:19AM  What Are The Drivers Of RXi Pharmaceuticals Corporations (RXII) Risks? Simply Wall St.
Nov-15-17 07:20AM  Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre ACCESSWIRE
Nov-13-17 11:53AM  Edited Transcript of RXII earnings conference call or presentation 8-Nov-17 9:30pm GMT Thomson Reuters StreetEvents +6.19%
07:05AM  RXi Pharmaceuticals and Gustave Roussy Announce Research Collaboration PR Newswire
Nov-08-17 12:50PM  RXi Pharmaceuticals Corporation to Host Earnings Call ACCESSWIRE -6.67%
07:05AM  RXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights PR Newswire
Nov-07-17 07:05AM  RXi Pharmaceuticals Announces Participation in Leading European Healthcare Forums and Conferences PR Newswire
Nov-01-17 07:05AM  RXi Pharmaceuticals to Webcast Third Quarter 2017 Financial Results on Wednesday, November 8, 2017 PR Newswire
Oct-11-17 07:05AM  RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum PR Newswire +11.96%
Oct-05-17 08:45AM  Streetwise Reports Interviews Executives at Biotech Company with Transformative RNAi Delivery System Marketwired +8.22%
Sep-25-17 12:00PM  RXi Pharmaceuticals sd-rxRNA: Better delivery than Amazon! Zacks Small Cap Research
Sep-19-17 07:10AM  Featured Company News - RXi Pharma's Chief Business Officer, Alexey Eliseev, to Leave the Company ACCESSWIRE
07:05AM  RXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference PR Newswire
Sep-18-17 07:05AM  RXi Pharmaceuticals to Present at BioPharm America's 10th Annual International Partnering Conference PR Newswire
Sep-15-17 04:30PM  RXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business Officer PR Newswire
07:05AM  BioAxone BioSciences Awarded NINDS SBIR Funding for the Development of Self-Delivering RNAi (sd-rxRNA®) for the Treatment of Spinal Cord Injury PR Newswire
Sep-06-17 07:05AM  RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts PR Newswire
Aug-31-17 07:05AM  RXi Pharmaceuticals Corporation Selected to Present at the 8th Annual Investing for Cures Forum PR Newswire
Aug-17-17 04:39PM  Edited Transcript of RXII earnings conference call or presentation 10-Aug-17 8:30pm GMT Thomson Reuters StreetEvents +5.68%
Aug-10-17 12:30PM  Investor Network: RXi Pharmaceuticals Corporation to Host Earnings Call ACCESSWIRE
07:05AM  RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights PR Newswire
Aug-09-17 07:05AM  RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15.0 Million PR Newswire +5.34%
Aug-08-17 07:05AM  RXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing PR Newswire
Aug-03-17 08:05AM  RXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain Compliance with Listing Requirements PR Newswire
07:05AM  RXi Pharmaceuticals to Webcast Second Quarter 2017 Financial Results on Thursday, August 10, 2017 PR Newswire
Jul-10-17 08:00AM  Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals Corporation and Exelixis Inc. Accesswire -11.04%
Jul-06-17 07:05AM  RXi Pharmaceuticals Provides Update on Clinical Development Programs in New SNNLive Video Interview with StockNewsNow.com Accesswire +7.11%
Jun-21-17 07:05AM  RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring PR Newswire +5.54%
Jun-15-17 07:18AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating RXi Pharmaceuticals Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire -9.66%
Jun-12-17 07:05AM  RXi Pharmaceuticals Announces the Initiation of its Consumer Testing Program with RXI-231 PR Newswire
Jun-08-17 11:44AM  The Life Sciences Report Examines RXi Pharmaceuticals Expanded Collaboration with Norwegian Cancer Firm and Gears Up for 2017 Milestones Marketwired +7.84%
07:05AM  RXi Pharmaceuticals to Present at the Marcum MicroCap Conference PR Newswire
Jun-07-17 07:05AM  RXi Pharmaceuticals Corporation Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors PR Newswire
May-23-17 07:05AM  RXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum PR Newswire
May-22-17 07:06AM  PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology GlobeNewswire
May-12-17 02:18PM  Edited Transcript of RXII earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:05AM  RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights PR Newswire
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. RXi Pharmaceuticals Corporation has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.